$60.46-0.03 (-0.05%)
Veracyte, Inc.
Veracyte, Inc. in the Healthcare sector is trading at $60.46 with a market capitalization of $4.1B. Wall Street consensus targets $49.10 (10 analysts), implying a -18.8% move over the next 12 months. The stock is currently near its 52-week high of $60.83, remaining 54.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $139.07M↓ | $140.64M↑ | $131.87M↑ | $130.16M↑ | $114.47M |
| Gross Profit | $101.16M↓ | $101.97M↑ | $91.28M↑ | $89.77M↑ | $79.51M |
| Operating Income | $22.65M↓ | $39.91M↑ | $23.11M↑ | $14.31M↑ | $2.90M |
| Net Income | $28.71M↓ | $41.15M↑ | $19.14M↑ | -$980,000↓ | $7.05M |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions.
Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is on a run.
Tech futures are rising modestly despite President Trump's threat to resume bombing Iran. Fed chief Kevin Warsh's comments loom.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Veracyte’s latest analyst update comes with no change in the price target, which can be just as informative as a revision. With fresh information in hand but no shift in the target, the message for you as an investor is more about stability than surprise. Read on to see how to interpret this kind of unchanged call and how to keep tracking the story as the narrative around Veracyte continues to evolve. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies...